a study to assess the knowledge and practices of self medication
... age of 16, nearly all adolescents have taken medicine independently. There is considerable variation, however, in the age at which independent self-care is achieved, as well as in the accuracy of medication and dosage selection.10 Stoelben and colleagues evaluated the medication knowledge of a group ...
... age of 16, nearly all adolescents have taken medicine independently. There is considerable variation, however, in the age at which independent self-care is achieved, as well as in the accuracy of medication and dosage selection.10 Stoelben and colleagues evaluated the medication knowledge of a group ...
highlights of prescribing information
... For topical use only; Picato® gel is not for oral, ophthalmic, or intravaginal use. Avoid transfer of Picato® gel to periocular area [see Warnings and Precautions (5.1)]. Avoid application near and around the mouth and lips. For the treatment of actinic keratosis on the face or scalp Picato® gel, 0. ...
... For topical use only; Picato® gel is not for oral, ophthalmic, or intravaginal use. Avoid transfer of Picato® gel to periocular area [see Warnings and Precautions (5.1)]. Avoid application near and around the mouth and lips. For the treatment of actinic keratosis on the face or scalp Picato® gel, 0. ...
EffEcts of MEMantinE on Pain in PatiEnts REtRosPEctivE study M
... before being increased by 5 or 10mg every 4-7 days, as tolerated, to a maximumdose of 40mg60mg, as tolerated. In all, 13 patients showed complete remission from CRPS with VAS 0 and the disappearance of allodynea for at least nine months after the use of memantine. In addition, 18 patients showed par ...
... before being increased by 5 or 10mg every 4-7 days, as tolerated, to a maximumdose of 40mg60mg, as tolerated. In all, 13 patients showed complete remission from CRPS with VAS 0 and the disappearance of allodynea for at least nine months after the use of memantine. In addition, 18 patients showed par ...
qa-lamotrigine-in-breastfeeding
... Medicines Q&As appetite, neuromotor hyperexcitability and irritability and occurred 2 weeks after cessation of breastfeeding. Symptoms resolved within 48 hours of treatment of the infant with lamotrigine 1 mg/kg daily. Neuromotor development was normal 1 month after discontinuation of therapy (12). ...
... Medicines Q&As appetite, neuromotor hyperexcitability and irritability and occurred 2 weeks after cessation of breastfeeding. Symptoms resolved within 48 hours of treatment of the infant with lamotrigine 1 mg/kg daily. Neuromotor development was normal 1 month after discontinuation of therapy (12). ...
Pharmacological Management of Persistent Pain in Older
... patients with functional impairment or diminished quality of life are candidates for pharmacological therapy, with intervention decisions based on careful weighing of risks and benefits. Positive outcomes are maximized when clinicians are knowledgeable about the drugs they prescribe and regularly mo ...
... patients with functional impairment or diminished quality of life are candidates for pharmacological therapy, with intervention decisions based on careful weighing of risks and benefits. Positive outcomes are maximized when clinicians are knowledgeable about the drugs they prescribe and regularly mo ...
How to safely prescribe long-acting opioids Feature article
... Pure agonist opioids include morphine, oxycodone, fentanyl, hydromorphone, and oxymorphone, to name a few. The analgesic or adverse effects of these agents do not reach a ceiling, which means when the dose increases, there is generally an increase in the analgesic activity and potential for adverse ...
... Pure agonist opioids include morphine, oxycodone, fentanyl, hydromorphone, and oxymorphone, to name a few. The analgesic or adverse effects of these agents do not reach a ceiling, which means when the dose increases, there is generally an increase in the analgesic activity and potential for adverse ...
Novel Fluorescent Probes Detect Different Types Of CYP450
... interactions. Testing compounds early in drug discovery for these unwanted interactions will permit elimination of unsuitable compounds and chemical series from further drug development. With the everexpanding pool of candidate drugs and increasing number of hits emerging from primary screening this ...
... interactions. Testing compounds early in drug discovery for these unwanted interactions will permit elimination of unsuitable compounds and chemical series from further drug development. With the everexpanding pool of candidate drugs and increasing number of hits emerging from primary screening this ...
Marijuana Myths and Facts
... It is almost as if most parents expect their kids to experiment with it. However, the facts don’t seem to support the blatant lack of concern over “pot smoking.” This document brings to light the facts surrounding marijuana. You may be surprised at what you ...
... It is almost as if most parents expect their kids to experiment with it. However, the facts don’t seem to support the blatant lack of concern over “pot smoking.” This document brings to light the facts surrounding marijuana. You may be surprised at what you ...
Fact sheets
... sclerosis. In summary, the transformation of the company is well under way.” Otto Schwarz, Chief Operating Officer, commented: “We continue to be extremely pleased with the transformation of our PAH portfolio. For the first time, in the third quarter, more than 50% of our sales came from our new out ...
... sclerosis. In summary, the transformation of the company is well under way.” Otto Schwarz, Chief Operating Officer, commented: “We continue to be extremely pleased with the transformation of our PAH portfolio. For the first time, in the third quarter, more than 50% of our sales came from our new out ...
Intravenous Ondansetron as Antiemetic Prophylaxis for
... and duration of anesthesia, and type of surgery involved.(13) A higher incidence of PONV has also been reported in younger patients, with the incidence rate decreasing by 13% for every 10–year increase in age.(14) Women are twice as likely to exhibit PONV as their male counterparts.(15) The use of n ...
... and duration of anesthesia, and type of surgery involved.(13) A higher incidence of PONV has also been reported in younger patients, with the incidence rate decreasing by 13% for every 10–year increase in age.(14) Women are twice as likely to exhibit PONV as their male counterparts.(15) The use of n ...
ketamine - Yorkshire and the Humber Deanery
... given advance notice of at least a week so that the drug may be ordered. The patient should be given an information leaflet about Ketamine that should include on it who they should contact in the event of any problems ...
... given advance notice of at least a week so that the drug may be ordered. The patient should be given an information leaflet about Ketamine that should include on it who they should contact in the event of any problems ...
Slide 1
... d4T + ddI a - these drugs have overlapping toxicities [A-II] TDF + 3TC + ABC b − this regimen selects for the K65R mutation and high incidence of early virologic failure [A-III] TDF + 3TC + ddI c - this regimen selects for the K65R mutation and high incidence of early virologic failure [A-III] TDF + ...
... d4T + ddI a - these drugs have overlapping toxicities [A-II] TDF + 3TC + ABC b − this regimen selects for the K65R mutation and high incidence of early virologic failure [A-III] TDF + 3TC + ddI c - this regimen selects for the K65R mutation and high incidence of early virologic failure [A-III] TDF + ...
Advicor® (niacin extended-release/lovastatin tablets)
... also falls substantially during treatment with lovastatin. Since each LDL-C particle contains one molecule of Apo B, and since little Apo B is found in other lipoproteins, this strongly suggests that lovastatin does not merely cause cholesterol to be lost from LDL-C, but also reduces the concentrati ...
... also falls substantially during treatment with lovastatin. Since each LDL-C particle contains one molecule of Apo B, and since little Apo B is found in other lipoproteins, this strongly suggests that lovastatin does not merely cause cholesterol to be lost from LDL-C, but also reduces the concentrati ...
Amber Initiation Guideline
... control. There are clear disadvantages/risks associated with NOAC as described above. Patients taking warfarin for indications other than anticoagulation in non-valvular AF, unless licensed in these groups. Patients with mitral valve disease or mechanical heart valve replacements (unlicensed in this ...
... control. There are clear disadvantages/risks associated with NOAC as described above. Patients taking warfarin for indications other than anticoagulation in non-valvular AF, unless licensed in these groups. Patients with mitral valve disease or mechanical heart valve replacements (unlicensed in this ...
Current treatment of oral candidiasis: A literature review
... Candidiasis or oral candidosis is one of the most common human opportunistic fungal infections of the oral cavity. This pathology has a wide variety of treatment which has been studied until these days. The present study offers a literature review on the treatment of oral candidiasis, with the purpo ...
... Candidiasis or oral candidosis is one of the most common human opportunistic fungal infections of the oral cavity. This pathology has a wide variety of treatment which has been studied until these days. The present study offers a literature review on the treatment of oral candidiasis, with the purpo ...
Opioid Addiction Treatment Pharmacotherapy
... • Variation of methadone binding to plasma proteins, such as those produced by marked changes in α1-acid glycoprotein levels, might significantly alter methadone pharmacokinetics. • Within each individual, there is a genetic polymorphism of α1-acid glycoprotein • However, the pharmacological consequ ...
... • Variation of methadone binding to plasma proteins, such as those produced by marked changes in α1-acid glycoprotein levels, might significantly alter methadone pharmacokinetics. • Within each individual, there is a genetic polymorphism of α1-acid glycoprotein • However, the pharmacological consequ ...
Prescriptions Pain Medications FAQs
... Controlled substances that are prescription drugs, such as opioids, are essential for the care of patients but carry a risk that goes beyond the usual clinical concern about toxicity. These drugs can become the object of abuse and addiction or be a target for diversion to an illicit market. This pot ...
... Controlled substances that are prescription drugs, such as opioids, are essential for the care of patients but carry a risk that goes beyond the usual clinical concern about toxicity. These drugs can become the object of abuse and addiction or be a target for diversion to an illicit market. This pot ...
TAMIFLU Product Monograph
... Efficacy of TAMIFLU in the treatment of subjects with chronic cardiac disease and/or respiratory disease has not been established. No difference in the incidence of complications was observed between the treatment and placebo groups in this population. No information is available regarding treatment ...
... Efficacy of TAMIFLU in the treatment of subjects with chronic cardiac disease and/or respiratory disease has not been established. No difference in the incidence of complications was observed between the treatment and placebo groups in this population. No information is available regarding treatment ...
FAQ in Word format - Help for Headaches
... Controlled substances that are prescription drugs, such as opioids, are essential for the care of patients but carry a risk that goes beyond the usual clinical concern about toxicity. These drugs can become the object of abuse and addiction or be a target for diversion to an illicit market. This pot ...
... Controlled substances that are prescription drugs, such as opioids, are essential for the care of patients but carry a risk that goes beyond the usual clinical concern about toxicity. These drugs can become the object of abuse and addiction or be a target for diversion to an illicit market. This pot ...
Drug Therapy
... cholesterol concentrations above which diet and drug therapy should be initiated, as well as the goals of therapy, have been defined by the National Cholesterol Education Program (Table 3).21 The target serum LDL cholesterol concentration is less than 160 mg per deciliter (4.3 mmol per liter) for pa ...
... cholesterol concentrations above which diet and drug therapy should be initiated, as well as the goals of therapy, have been defined by the National Cholesterol Education Program (Table 3).21 The target serum LDL cholesterol concentration is less than 160 mg per deciliter (4.3 mmol per liter) for pa ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.